IP Library Granted Patent US 10,799,612
Granted Patent B2
US 10,799,612 · App. 16/068,122 · Granted Oct 13, 2020

Implanted device

Inventors: Deyuan Zhang (Shenzhen, CN); Liping Chen (Shenzhen, CN); Haiping Qi (Shenzhen, CN); Hongtao Sun (Shenzhen, CN); Jun Hu (Shenzhen, CN); Wenjiao Lin (Shenzhen, CN)
Assignee: Lifetech Scientific (Shenzhen) Co. Ltd.
A61L27/047A61B17/68A61F2/02A61F2/82A61K6/84A61K45/06A61L27/00A61L27/427A61L27/58A61L31/022A61L31/148A61P29/00A61P37/08C07F3/06C22C1/02C22C18/00C22F1/16A61F2002/823A61F2220/0016A61F2240/001A61L27/045A61L31/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,799,612
App. No.
16/068,122
Granted
Oct 13, 2020
Kind
B2
Abstract

Disclosed is an implanted device, comprising a device base body and an active drug, wherein the device base body is pure zinc and/or a zinc alloy, the zinc content in the device base body is 0.1-100%, and the active drug comprises anti-allergic drugs. After the implantation of the implanted device into the human body, the surrounding tissues of the implant would not have a clear hypersensitive reaction due to the presence of the anti-allergic drugs, and the implanted device can be used to be implanted into the body for supporting organ chambers, to fill the hollow chambers of the organs and tissues or as orthopaedic implants etc.

Claims (3)

1. An implanted device, consisting of a device substrate that has 95 percent of zinc, 4.5 percent of iron, and 0.5 percent of inclusion elements that do not include zinc or iron; the device substrate has a surface coated with a coating that is a mixture of polylactic acid, dexamethasone, and gluconic acid, with the mass ratio of the polylactic acid to the dexamethasone in the coating being 2:1; wherein the coating on the surface of the device substrate has a thickness of 2 μm, and the content of the dexamethasone on the surface of the device substrate is 100 ug/cm 2 .

2. The implanted device according to claim 1 , wherein the gluconic acid and the zinc in the device substrate form a complex in body fluid.

3. The implanted device according to claim 1 , wherein the implanted device is a stent, an occluder, an orthopedic implant, a dental implant, a suture line or a bolt; the stent is a vascular stent, a tracheal stent, an esophageal stent, a urethral stent, an intestinal stent or a biliary stent; and the orthopedic implant is a fixing screw, a fixing rivet or a bone plate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2021
From: LIFETECH SCIENTIFIC (SHENZHEN) CO. LTD.
To: BIOTYX MEDICAL (SHENZHEN) CO., LTD.
Reel/Frame 055086/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 4, 2018
From: ZHANG, DEYUAN; CHEN, LIPING; QI, HAIPING; SUN, HONGTAO; HU, JUN; LIN, WENJIAO
To: LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD.
Reel/Frame 046266/0057 →
Priority Claims (1)
CN 2016 1 0016894 · Jan 8, 2016 · national
Continuity (1)
Related Publication 20190008996A1 · Jan 10, 2019